Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5JV8G)

• Drug Name: 7,3',4'-trihydroxyisoflavone Drug Info
• Synonyms: 3',4',7-Trihydroxyisoflavone; 3'-Hydroxydaidzein; 485-63-2; 3-(3,4-Dihydroxyphenyl)-7-hydroxy-4H-chromen-4-one; 7,3',4'-Trihydroxyisoflavone; UNII-T08Y239E7Y; CHEMBL13486; CHEBI:50399; 3',4',7-trihydroxy isoflavone; DDKGKOOLFLYZDL-UHFFFAOYSA-N; 3'',4'',7-trihydroxyisoflavone; T08Y239E7Y; 3-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one; 3-(3,4-dihydroxyphenyl)-7-hydroxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3,4-dihydroxyphenyl)-7-hydroxy-; 47X; Orita-13; 3l5r; AC1NR4TZ; SCHEMBL73012; BIDD:ER0118; GTPL9985

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5284648
  ChEBI ID: CHEMBL50399
  CAS Number: CAS 485-63-2
  TTD Drug ID: DM5JV8G

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosinase (TYR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[3]
Monobenzone	DMVJS2K	Vitiligo	ED63.0	Approved	[3]
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[4]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[5]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[6]
MKC-1106-MT	DMXKOW6	Melanoma	2C30	Phase 2	[7]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Melanoma	2C30	Phase 2	[8]
PMID29130358-Compound-Figure11(3)	DMSME2B	N. A.	N. A.	Patented	[9]
Benzothiazole analog 1	DMHXFCQ	Albinism	EC23.2	Patented	[10]
Monoamine derivative 2	DMAZ6DI	Albinism	EC23.2	Patented	[10]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[11]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[12]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[13]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[14]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[15]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[16]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[17]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[18]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[19]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosinase (TYR)	TTULVH8	TYRO_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[2]

References

• [1] Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1162-4.
• [2] 7,3',4'-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species. Toxicology. 2012 Dec 16;302(2-3):221-32. doi: 10.1016/j.tox.2012.08.003. Epub 2012 Aug 15.
• [3] Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
• [4] Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
• [5] National Cancer Institute Drug Dictionary (drug id 685201).
• [6] An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
• [7] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [8] ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
• [9] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [10] Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
• [11] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [12] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [13] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [14] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [15] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [16] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [17] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [18] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [19] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.